Reduction of nontarget infection and systemic toxicity by targeted delivery of conditionally replicating viruses transported in mesenchymal stem cells
about
Mesenchymal Stem Cell-Mediated Effects of Tumor Support or SuppressionStem Cell-Based Cell Carrier for Targeted Oncolytic Virotherapy: Translational Opportunity and Open QuestionsPromising oncolytic agents for metastatic breast cancer treatmentMesenchymal stem cells as a vector for the inflammatory prostate microenvironmentOncolytic Adenovirus-Loaded Menstrual Blood Stem Cells Overcome the Blockade of Viral Activity Exerted by Ovarian Cancer AscitesAdvances in mesenchymal stem cell-mediated gene therapy for cancer.Bortezomib sensitizes non-small cell lung cancer to mesenchymal stromal cell-delivered inducible caspase-9-mediated cytotoxicity.Mesenchymal stem cells derived from adipose tissue vs bone marrow: in vitro comparison of their tropism towards gliomas.Mesenchymal stem cells at the intersection of cell and gene therapy.Mesenchymal stem cells: from experiment to clinic.Oncolytic virotherapy for ovarian cancer.Pharmacokinetic study of neural stem cell-based cell carrier for oncolytic virotherapy: targeted delivery of the therapeutic payload in an orthotopic brain tumor model.Optimizing patient derived mesenchymal stem cells as virus carriers for a phase I clinical trial in ovarian cancer.Mesenchymal Stromal Cells for Linked Delivery of Oncolytic and Apoptotic Adenoviruses to Non-small-cell Lung Cancers.Gene therapy and virotherapy: novel therapeutic approaches for brain tumors.Using living cells to transport therapeutic genes for cancer treatment.Glioblastoma multiforme: State of the art and future therapeutics.Application of conditionally replicating adenoviruses in tumor early diagnosis technology, gene-radiation therapy and chemotherapy.Delivery of improved oncolytic adenoviruses by mesenchymal stromal cells for elimination of tumorigenic pancreatic cancer cells.Engineered adenoviruses combine enhanced oncolysis with improved virus production by mesenchymal stromal carrier cells.The use of hypoxic cultured mesenchymal stem cell for oncolytic virus therapy.Human Menstrual Blood-Derived Mesenchymal Stem Cells as Potential Cell Carriers for Oncolytic Adenovirus.Mesenchymal stem cells enhance the oncolytic effect of Newcastle disease virus in glioma cells and glioma stem cells via the secretion of TRAIL.Concise Review: Mesenchymal Stem Cell-Based Drug Delivery: The Good, the Bad, the Ugly, and the Promise
P2860
Q26773413-A9331BD5-0D64-4A14-AF40-BE5E71408914Q26775038-911AFA7D-F838-4997-982D-DB2994F2F172Q26830620-7BE579BB-3CB7-480A-9732-6388E8C8EC19Q26853374-B9E7CFA0-27CA-497C-8945-73C259B3E009Q33904378-8AFF76F5-D41E-4C7D-A683-A062A5A9A468Q34135233-BF7129D7-2E32-4296-B77B-126690A15775Q34576976-9C71AF65-326D-4989-AE0F-BF4F0193D123Q34647951-C58D2693-F107-43AE-BCA6-A1A2F51FE43BQ34676808-15ECB84C-EE6D-46C9-B0AE-2A0EDDF8C1B5Q35240668-7844F363-8519-4465-A9FF-7DFD2B69EBE2Q35597082-438AD3F8-3F6C-426A-95CB-C94DB9425406Q35973436-3AE5696E-3661-4119-A790-A031827716A7Q36597119-7352C328-3DF3-4F47-9DF0-60F910DAD434Q36757082-50686DDF-7609-4E63-8FE0-CC25E83C105DQ37804933-DB03CBA9-471C-464A-AB36-4BDB5A9B20EBQ37829108-683D933D-AE7A-4FB1-8DAC-082D2D17302EQ38225874-3537097A-F730-41DB-AC58-D2A969B5273EQ38828208-54A5249A-1973-4113-AC91-977E730BEF7CQ38914555-A89F3DE6-9C6E-421F-BA48-C34B693D73CFQ38918317-152F262B-9A8D-462F-A962-5990CFDCA7FBQ39160337-59C0C32D-901B-47B8-B9F7-4F169237D7DDQ40092902-B82E73FC-E238-4715-9DC8-E82CBC44EDC2Q40511505-8F74AD5C-4D44-46B6-B9DF-E903FE6FF7E4Q58804653-C60988ED-CB62-4CE9-86FF-853A4451FD0D
P2860
Reduction of nontarget infection and systemic toxicity by targeted delivery of conditionally replicating viruses transported in mesenchymal stem cells
description
2009 nî lūn-bûn
@nan
2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Reduction of nontarget infecti ...... rted in mesenchymal stem cells
@ast
Reduction of nontarget infecti ...... rted in mesenchymal stem cells
@en
Reduction of nontarget infecti ...... rted in mesenchymal stem cells
@nl
type
label
Reduction of nontarget infecti ...... rted in mesenchymal stem cells
@ast
Reduction of nontarget infecti ...... rted in mesenchymal stem cells
@en
Reduction of nontarget infecti ...... rted in mesenchymal stem cells
@nl
prefLabel
Reduction of nontarget infecti ...... rted in mesenchymal stem cells
@ast
Reduction of nontarget infecti ...... rted in mesenchymal stem cells
@en
Reduction of nontarget infecti ...... rted in mesenchymal stem cells
@nl
P2093
P2860
P356
P1433
P1476
Reduction of nontarget infecti ...... rted in mesenchymal stem cells
@en
P2093
C Gomez-Manzano
E L Spaeth
F C Marini
M Andreeff
P2860
P2888
P304
P356
10.1038/CGT.2009.67
P577
2009-10-30T00:00:00Z